Nationwide Fund Advisors boosted its position in shares of Codexis, Inc. (NASDAQ:CDXS) by 15.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,568 shares of the biotechnology company’s stock after purchasing an additional 2,928 shares during the period. Nationwide Fund Advisors’ holdings in Codexis were worth $118,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CDXS. Baillie Gifford & Co. grew its holdings in Codexis by 23.3% during the 2nd quarter. Baillie Gifford & Co. now owns 1,461,413 shares of the biotechnology company’s stock valued at $7,965,000 after purchasing an additional 276,280 shares in the last quarter. Blair William & Co. IL grew its holdings in Codexis by 61.6% during the 2nd quarter. Blair William & Co. IL now owns 279,797 shares of the biotechnology company’s stock valued at $1,525,000 after purchasing an additional 106,700 shares in the last quarter. William Blair Investment Management LLC grew its holdings in Codexis by 10.5% during the 2nd quarter. William Blair Investment Management LLC now owns 1,090,072 shares of the biotechnology company’s stock valued at $5,941,000 after purchasing an additional 103,233 shares in the last quarter. Essex Investment Management Co. LLC grew its holdings in Codexis by 40.1% during the 2nd quarter. Essex Investment Management Co. LLC now owns 288,876 shares of the biotechnology company’s stock valued at $1,574,000 after purchasing an additional 82,738 shares in the last quarter. Finally, Comprehensive Portfolio Management LLC acquired a new stake in Codexis during the 2nd quarter valued at $426,000. 63.65% of the stock is owned by institutional investors and hedge funds.

Codexis, Inc. (CDXS) opened at $5.85 on Tuesday. Codexis, Inc. has a fifty-two week low of $3.60 and a fifty-two week high of $7.95.

In other Codexis news, major shareholder Ventures Vii Affiliates F. Vivo sold 1,060,000 shares of the firm’s stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $5.78, for a total transaction of $6,126,800.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 9.80% of the stock is owned by company insiders.

A number of research firms recently weighed in on CDXS. Jefferies Group LLC raised their price target on shares of Codexis from $9.00 to $11.00 and gave the company a “buy” rating in a report on Friday, October 13th. HC Wainwright raised their price target on shares of Codexis from $8.00 to $8.50 and gave the company a “buy” rating in a report on Friday, October 13th. Zacks Investment Research raised shares of Codexis from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. ValuEngine raised shares of Codexis from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, BidaskClub raised shares of Codexis from a “sell” rating to a “hold” rating in a report on Saturday, August 19th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Codexis has a consensus rating of “Hold” and an average target price of $7.50.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/11/21/codexis-inc-cdxs-position-raised-by-nationwide-fund-advisors.html.

Codexis Company Profile

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Want to see what other hedge funds are holding CDXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Codexis, Inc. (NASDAQ:CDXS).

Institutional Ownership by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.